You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on CypComp Database.
Record Information
Version1.0
Creation Date2019-07-14 16:37:44 UTC
Last Updated2019-10-01 21:41:47 UTC
CypComp IDCC02282
Compound Information
NameGalantamine
Structure ImageAsutzqlvashgkv jdfrzjqesa n
InChIKeyASUTZQLVASHGKV-JDFRZJQESA-N
PubChem ID9651
CypCompound Information
SetCypBoM Training Set
Bonds of Metabolism (BoMs)
CYP1A2CYP2A6CYP2B6CYP2C8CYP2C9CYP2C19CYP2D6CYP2E1CYP3A4
  • Not Available
  • Not Available
  • Not Available
  • Not Available
  • Not Available
  • Not Available
  • <21,18;Cleavage;R1>
  • <21,H;Oxidation;R1>
  • <20,8;Cleavage;R2>
  • <20,H;Oxidation;R2>
  • Not Available
  • Not Available
References
  1. Bachus R, Bickel U, Thomsen T, Roots I, Kewitz H: The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. Pharmacogenetics. 1999 Dec;9(6):661-8. [PubMed:10634129 ]
  2. Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804. doi: 10.2165/11318070-000000000-00000. [PubMed:19902987 ]
  3. Mannens GS, Snel CA, Hendrickx J, Verhaeghe T, Le Jeune L, Bode W, van Beijsterveldt L, Lavrijsen K, Leempoels J, Van Osselaer N, Van Peer A, Meuldermans W: The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metab Dispos. 2002 May;30(5):553-63. doi: 10.1124/dmd.30.5.553. [PubMed:11950787 ]
Download FileCC02282.sdf